Latif Nasser

None of those prices are figured into it.

Okay?

I'm just giving you the cost of the drug.

So Leonard calls up one of his colleagues.

My name is Peter Bach.

I'm a physician at Memorial Sloan Kettering.

Peter is the number cruncher of the group.

He does the statistical analysis of, I don't know, the cost of care.

And Len grabbed him and ran him through all the data.

And we walked through the out-of-pocket expenses for Medicare beneficiaries.

Medicare beneficiaries, if they don't have additional insurance, 20 cents of every dollar they pay out-of-pocket.

And that number sort of hit him because he realized for Medicare patients, they'd be paying something like $2,000 out of pocket every month for just this drug.

$2,200, if I remember the number correctly.

For a lot of Medicare patients.

That's all of their money.

Never mind other drugs.

That's when I thought we should go public with it.

Memorial Sloan Kettering, they decide to boycott this drug.

Now, is that, I mean, I'm just stopping you because when you guys made that decision, was that, that feels like a big deal.

It did feel like a big deal, and it felt like a big enough deal that we decided to write the op-ed piece in the New York Times.